Cargando…

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herbreteau, Guillaume, Langlais, Alexandra, Greillier, Laurent, Audigier-Valette, Clarisse, Uwer, Lionel, Hureaux, José, Moro-Sibilot, Denis, Guisier, Florian, Carmier, Delphine, Madelaine, Jeannick, Otto, Josiane, Souquet, Pierre-Jean, Gounant, Valérie, Merle, Patrick, Molinier, Olivier, Renault, Aldo, Rabeau, Audrey, Morin, Franck, Denis, Marc G, Pujol, Jean-Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760916/ https://www.ncbi.nlm.nih.gov/pubmed/33261056 http://dx.doi.org/10.3390/jcm9123861

Ejemplares similares

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
por: Molinier, O., et al.
Publicado: (2021)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2022)

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
por: Barrière, Jérôme, et al.
Publicado: (2022)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial
por: Levallet, Guénaëlle, et al.
Publicado: (2016)

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
por: Barlesi, Fabrice, et al.
Publicado: (2020)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
por: Girard, N., et al.
Publicado: (2020)

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
por: Marolleau, Sophie, et al.
Publicado: (2023)

Préconisations pour protéger les patients de la filière oncologique face au variant Omicron
por: Barrière, Jérôme, et al.
Publicado: (2022)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
por: Toffart, Anne-Claire, et al.
Publicado: (2014)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients
por: Gounant, Valérie, et al.
Publicado: (2021)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
por: Bennouna, Jaafar, et al.
Publicado: (2018)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

COVID-19 — Journal de bord — 6/6/2020 : non, cette fois-ci, ce ne fut pas ma guerre !
por: Herbreteau, Denis
Publicado: (2020)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
por: Couraud, S., et al.
Publicado: (2013)

Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab
por: Benjamin, Lardinois, et al.
Publicado: (2021)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement
por: Barrière, Jérôme, et al.
Publicado: (2021)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy
por: Chouik, Yasmina, et al.
Publicado: (2023)

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2017)

Omicron variant: A clear and present danger for patients with cancer
por: Barrière, J., et al.
Publicado: (2022)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients
por: Pujol, J-L, et al.
Publicado: (2004)

COVID-19 : un scanner illustratif de l’atteinte pulmonaire
por: Barrot, Valère, et al.
Publicado: (2020)

Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
por: Denis, Marc G., et al.
Publicado: (2023)

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting
por: Falette-Puisieux, Manon, et al.
Publicado: (2023)

Genome and Epigenome Surveillance Processes Underlying UV Exposure in Plants
por: Molinier, Jean
Publicado: (2017)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial
por: Carrouel, Florence, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j9032ig6838h0oi5cldgnv904e